Brief: Neuren Pharmaceuticals Expects To Receive Revenue Over 2022 & 2023 For Rett Syndrome In U.S. Alone Of A$118 Mln
29/07/2022 02:23
July 29 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* EXPECTS TO RECEIVE REVENUE OVER 2022 & 2023 FOR RETT
SYNDROME IN
U.S. ALONE OF A$118 MILLION
Source text for Eikon: ID:nASX30jw49
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union